Strongbridge Biopharma (NASDAQ:SBBP) announces preliminary Q4 and full-year 2019 results and provided an update on key corporate priorities for 2020.
The Company anticipates that it will achieve KEVEYIS net product sales of ~$5.6M for Q4 and ~$21.7M for FY 2019, exceeding its previous $18M to $20M guidance range.
The Company projects that the full-year 2020 revenue guidance for KEVEYIS will be ~$26 to $27M.
Key Corporate Priorities for 2020: Complete enrollment in the Phase 3 LOGICS study of RECORLEV in endogenous Cushing’s syndrome. To date, the trial is more than 70 percent enrolled.
Report top-line results for the Phase 3 LOGICS study in Q2 or Q3 2020 and submit a NDA for RECORLEV to the FDA approx. six months after reporting top-line LOGICS results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.